Introduction: The best therapeutic strategy for patients with mechanical heart valves (MHVs) having acute ischemic stroke during treatment with vitamin K antagonists (VKAs) remain unclear. Being so, we compared the outcomes for: (i) full dose heparin along with VKA (bridging therapy group) and (ii) restarting VKA without heparin (nonbridging group). Patients and methods: For this multicenter observational cohort study, data on consecutive acute ischemic stroke patients with MHV was retrospectively collected from prospective registries. Propensity score matching (PSM) was adopted to adjust for any treatment allocation confounders. The primary outcome was the composite of stroke, systemic embolism, symptomatic cerebral bleeding, and major extracerebral bleeding at 90 days. Results: Overall, 255 out of 603 patients (41.3%) received bridging therapy: 36 (14.1%) had combined outcome, compared with 28 (8.0%) in the nonbridging group (adjusted OR 1.83; 95% CI 1.05-3.18; p = 0.03). Within the bridging group, 13 patients (5.1%) compared to 12 (3.4%) in the nonbridging group had an ischemic outcome (adjusted OR 1.71; 95% CI 0.84-3.47; p = 0.2); major bleedings were recorded in 23 (9.0%) in the bridging group and 16 (4.6%) in the nonbridging group (adjusted OR 1.88; 95% CI 0.95-3.73; p = 0.07). After PSM, 36 (14.2%) of the 254 bridging patients had combined outcome, compared with 23 (9.1%) of 254 patients in the nonbridging group (OR 1.66; 95% CI 0.95-2.85; p = 0.07). Conclusion: Acute ischemic stroke patients with MHV undergoing bridging therapy had a marginally higher risk of ischemic or hemorrhagic events, compared to nonbridging patients.
Anticoagulation in acute ischemic stroke patients with mechanical heart valves: To bridge or not with heparin. The ESTREM study / Paciaroni, Maurizio; Caso, Valeria; Romoli, Michele; Becattini, Cecilia; Salerno, Alexander; Rapillo, Costanza; Simonnet, Fanny; Strambo, Davide; Canavero, Isabella; Zedde, Marialuisa; Pascarella, Rosario; Sohn, Sung-Il; Sacco, Simona; Ornello, Raffaele; Barlinn, Kristian; Schoene, Daniela; Rahmig, Jan; Mosconi, Maria Giulia; Leone De Magistris, Ilaria; Alberti, Andrea; Venti, Michele; Silvestrelli, Giorgio; Ciccone, Alfonso; Padroni, Marina; Laudisi, Michele; Zini, Andrea; Gentile, Luana; Kargiotis, Odysseas; Tsivgoulis, Georgios; Tassi, Rossana; Guideri, Francesca; Acampa, Maurizio; Masotti, Luca; Grifoni, Elisa; Rocco, Alessandro; Diomedi, Marina; Karapanayiotides, Theodore; Engelter, Stefan T; Polymeris, Alexandros A; Zietz, Annaelle; Bandini, Fabio; Caliandro, Pietro; Reale, Giuseppe; Moci, Marco; Zauli, Aurelia; Cappellari, Manuel; Emiliani, Andrea; Gasparro, Antonio; Terruso, Valeria; Mannino, Marina; Giorli, Elisa; Toni, Danilo; Andrighetti, Marco; Falcou, Anne; Palaiodimou, Lina; Ntaios, George; Sagris, Dimitrios; Karagkiozi, Efstathia; Adamou, Anastasia; Halvatsiotis, Panagiotis; Flomin, Yuriy; Scoditti, Umberto; Genovese, Antonio; Popovic, Nemanja; Pantoni, Leonardo; Mele, Francesco; Molitierno, Nicola; Lochner, Piergiorgio; Pezzini, Alessandro; Del Sette, Massimo; Sassos, Davide; Giannopoulos, Sotirios; Kosmidou, Maria; Ntais, Evangelos; Lotti, Enrico Maria; Mastrangelo, Vincenzo; Chiti, Alberto; Naldi, Andrea; Vanacker, Peter; Ferrante, Mario; Volodina, Vera; Mancuso, Michelangelo; Giannini, Nicola; Baldini, Marco; Vadikolias, Kostantinos; Kitmeridou, Sofia; Saggese, Carlo Emanuele; Tassinari, Tiziana; Saia, Valentina; Michel, Patrik. - In: EUROPEAN STROKE JOURNAL. - ISSN 2396-9881. - 8:4(2023), pp. 1030-1040. [10.1177/23969873231186863]
Anticoagulation in acute ischemic stroke patients with mechanical heart valves: To bridge or not with heparin. The ESTREM study
Gentile, Luana;Toni, Danilo;Andrighetti, Marco;Falcou, Anne;Pantoni, Leonardo;
2023
Abstract
Introduction: The best therapeutic strategy for patients with mechanical heart valves (MHVs) having acute ischemic stroke during treatment with vitamin K antagonists (VKAs) remain unclear. Being so, we compared the outcomes for: (i) full dose heparin along with VKA (bridging therapy group) and (ii) restarting VKA without heparin (nonbridging group). Patients and methods: For this multicenter observational cohort study, data on consecutive acute ischemic stroke patients with MHV was retrospectively collected from prospective registries. Propensity score matching (PSM) was adopted to adjust for any treatment allocation confounders. The primary outcome was the composite of stroke, systemic embolism, symptomatic cerebral bleeding, and major extracerebral bleeding at 90 days. Results: Overall, 255 out of 603 patients (41.3%) received bridging therapy: 36 (14.1%) had combined outcome, compared with 28 (8.0%) in the nonbridging group (adjusted OR 1.83; 95% CI 1.05-3.18; p = 0.03). Within the bridging group, 13 patients (5.1%) compared to 12 (3.4%) in the nonbridging group had an ischemic outcome (adjusted OR 1.71; 95% CI 0.84-3.47; p = 0.2); major bleedings were recorded in 23 (9.0%) in the bridging group and 16 (4.6%) in the nonbridging group (adjusted OR 1.88; 95% CI 0.95-3.73; p = 0.07). After PSM, 36 (14.2%) of the 254 bridging patients had combined outcome, compared with 23 (9.1%) of 254 patients in the nonbridging group (OR 1.66; 95% CI 0.95-2.85; p = 0.07). Conclusion: Acute ischemic stroke patients with MHV undergoing bridging therapy had a marginally higher risk of ischemic or hemorrhagic events, compared to nonbridging patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
10.1177_23969873231186863.pdf
solo gestori archivio
Note: Paciaroni_Anticoagulation_2023
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.67 MB
Formato
Adobe PDF
|
1.67 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
